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We describe the first clinical isolate of Bordetella petrii
from a patient with mandibular osteomyelitis. The only pre-
viously documented isolation of B. petrii occurred after the
initial culture of a single strain from an environmental
source.
A
67-year-old man visited an emergency dental clinic,
where he complained of toothache in the lower right
mandibular quadrant. Examination showed a root-filled
lower right canine tooth that was mobile and tender to per-
cussion. The tooth was extracted uneventfully under local
anesthesia. The patient returned after several days with
pain at the extraction site. Alocalized alveolar osteitis was
diagnosed, and local debridement measures were institut-
ed. These measures proved unsuccessful, and repeat exam-
ination showed submandibular lymphadenopathy and
tenderness to palpation in the buccal sulcus in the extrac-
tion site. Radiographs showed no abnormality at this stage. 
A course of oral amoxicillin (250 mg, every 8 h for 5
days) followed by oral metronidazole (200 mg every 8 h
for 5 days) was prescribed. Symptoms persisted, with
increasing severity of pain in the affected area, and the
patient was referred to a tertiary referral center. On exam-
ination there, the patient had normal full blood count,
hematinics, and glucose levels. Ultrasound examination of
the submental soft tissue region did not indicate any abnor-
mal pathology. Radiographs showed radiolucencies in the
bone surrounding the extraction site. During this period a
3-week course of oral co-amoxiclav (375 mg, every 8 h)
was prescribed. A bone biopsy was performed under local
anesthesia, and a diagnosis of mandibular osteomyelitis
was made.
A portion of the bone biopsy specimen was cultured in
10 mLFastidious Anaerobe Broth (FAB) (BioConnections,
Wetherby, UK) and incubated for 48 h at 37°C in air. After
48 h, the FAB was subcultured onto 1) Fastidious
Anaerobe Agar (FAA, BioConnections), incubated for 72
h at 37°C under anaerobic conditions, and 2) Columbia
Blood Agar (CBA, BioConnections), incubated for 72 h at
37°C under 5% CO2 atmospheric conditions. Culture on
both FAA and CBA showed a pure growth of a facultative
gram-negative bacillus that had not been identified with
routine laboratory protocols. Initial susceptibility testing
using disk diffusion indicated apparent susceptibility of the
isolate to erythromycin, gentamicin, ceftriaxone, and
piperacillin/tazobactam. The isolate was resistant to amox-
icillin, co-amoxiclav, tetracycline, clindamycin, ciproflo-
xacin, and metronidazole. After initial sensitivity results, a
6-week course of oral clarithromycin (500 mg, 8 hourly)
was begun. 
At follow-up appointments 3 months and 6 months
after antimicrobial drug therapy ceased, clinical and radi-
ographic findings were not unusual, and the infected area
healed successfully. Despite the successful clinical out-
come, the isolate was subsequently shown to be resistant to
clarithromycin in vitro (Table). Improvement of the
osteomyelitis may also have been facilitated by the biopsy
procedure, during which a sequestrum of bone was
removed.
The gram-negative bacillus (designated strain
GDH030510) was submitted to the Health Protection
Agency, Centre for Infections, London, for identification.
Preliminary tests results were consistent with those
described for members of the genus Bordetella. Colonies
had the following phenotypic characteristics: positive
reaction for oxidase and negative reaction for urease pro-
duction, motility using the hanging-drop method at 37°C,
and slide agglutination with B. pertussis and B. paraper-
tussis antiserum (Difco, Shannon, Ireland). The organism
could be cultured on MacConkey agar and was non-
hemolytic on blood agar. Genomic DNA was extracted by
using the InstaGene Purification Matrix (BioRad,
Hercules, CA, USA). DNA amplification of small-subunit
(SSU) rRNA genes was performed by using primers 27f
and 1525r (1). Amplification and sequencing of the gene
for the Bordetella outer membrane protein A (ompA) and
the RisA response regulator (risA) were as described by
von Wintzingerode et al. (2). Reaction mixes contained the
following: 2 mmol/L MgCl2, 10 mmol/L Tris-HCl (pH
8.3), 50 mmol/L KCl, 0.05% W-1 (Invitrogen, Paisley,
UK), 0.2 µmol/L of each deoxynucleotide (Roche Applied
Science, Lewes, UK) 20 pmol of each primer (MWG
Biotech, Milton Keynes, UK), 2.5 U of Taq DNA poly-
merase (Invitrogen), 1.0 mol/L betaine (Sigma-Aldrich,
Gillingham, UK), and 10 µLtemplate DNA. Amplification
was performed in a DNA Engine (MJ Research, Bio-Rad)
by using 35 cycles of denaturation of 1 min at 94°C, 1 min
at 55°C, and 2 min at 72°C and a final step at 72°C for 3
min. Amplicons from triplicate samples were pooled and
purified with Montage PCR96 filter plates (Millipore,
Watford, UK). For the rRNA gene, nucleotide sequence
was determined by using the primers used for amplifica-
tion, together with internal primers (1). Sequencing was
performed with the Dye Terminator Cycle Sequencing kit
(Beckman Coulter, High Wycombe, UK) and analyzed on
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according to the manufacturer’s instructions. Contig
assembly and sequence analyses were performed with
Kodon, version 2.0 (Applied Maths, Kortrijk, Belgium)
and BioNumerics, version 3.5 (Applied Maths). Consensus
sequence was compared with public databases with the
BLASTn program (http://www.ncbi.nlm.nih.gov/BLAST)
(3), and sequences with the greatest similarity were down-
loaded for further analysis.
The nucleotide sequences of the 16S rRNA gene, risA
gene, and ompAgene of strain GDH030510 have been sub-
mitted to the EMBL Nucleotide Sequence Database under
accession numbers AJ870969, AJ920265, and AJ920264,
respectively. The 1,486 nucleotides (nt) of the SSU rRNA
gene sequence that were determined showed a maximum
similarity of 99.3% (1,468/1,479 nt) with the 16S rRNA
gene from the type strain of B. petrii (GenBank accession
no. AJ249861). For all sequence analyses, regions not
present in all sequences and ambiguous bases were exclud-
ed. The species with the next highest similarities were B.
parapertussis, 98.4% (1,455/1,479 nt), and B. bronchisep-
tica, 98.3% (1,454/1,479 nt). The secondary structure of
the SSU rRNA from both strain GDH030510 and the sub-
mitted sequence for the type strain of B. petrii were com-
pared to that proposed for bacteria (4). Where possible
(i.e., in stems), supportive evidence from base-pairing was
sought. This analysis indicated that the assigned
nucleotides at 3 separate locations in the GenBank B. petrii
sequence were not supported, as they formed noncanonical
base-pairing (C-U vs. C-G [156, 165], U-U vs. A-U [824,
875], A-C vs. G-C [838, 848]; Escherichia coli numbering
[5]). Exclusion of these 3 bases increased the similarity to
99.5% (1,468/1,476 nt). The 445 nt of the risA gene
sequence of strain GDH030510 that were determined
showed a maximum similarity value of 93.9% (418/445 nt)
with the risA gene from the B. petrii type strain
(AJ242553). The species with the next highest similarities
were B. parapertussis, B. avium, B. bronchiseptica, and B.
pertussis, all with similarities of 88.3% (393/445 nt). The
414 nt of the ompA gene sequence that were determined
showed maximum a similarity value of 92.0% (381/414 nt)
with the ompA gene from the B. petrii type strain
(AJ242599). The species with the next highest similarities
were  B. bronchiseptica and  B. parapertussis, both with
similarities of 87.9% (364/414 nt).
Further susceptibility testing was undertaken, with
MICs determined by agar dilution on diagnostic sensitivi-
ty test agar (Oxoid, Basingstoke, UK) supplemented with
5% lysed horse blood, with inocula equivalent to 0.5 and 2
McFarland standards, and with incubation at 37°C in air
for 24 to 36 h to ensure adequate growth. No inoculum
effects were noted on MICs for any antimicrobial agents.
MICs are shown in the Table. 
Currently, the genus Bordetella comprises 8 species (2),
7 of which have been isolated from humans and a variety
of warm-blooded animals. Three of these species, B. per-
tussis, B. parapertussis, and B. bronchiseptica, are often
referred to as the classic Bordetella species (6); they are
closely related phylogenetically but have distinct host
ranges. B. pertussis is an obligate pathogen for humans and
is the etiologic agent of pertussis. B. parapertussis causes
a similar, usually milder, infection in humans, and B. para-
pertussis strains may also be isolated from sheep with
chronic pneumonia. Human isolates of B. parapertussis
are highly clonal and appear distinct from sheep isolates.
B. bronchiseptica is known to infect many mammals,
including humans, although human infection is rare and
usually occurs in immunocompromised hosts. B. avium is
pathogenic for birds, including poultry, and causes coryza
or rhinotracheitis in turkeys. Three other species of
Bordetella, B. hinzii, B. holmesii, and B. trematum, have
subsequently been described (7–9). B. hinzii is a commen-
sal of the respiratory tract of fowl but has some pathogen-
ic potential in immunocompromised humans (10) and was
implicated as the causative agent in a fatal case of sep-
ticemia (11). B. holmesii has been isolated from blood of
young adults, and nasopharyngeal specimens (9,12,13). B.
trematum has been isolated from human ear infections and
wounds, but its pathogenicity remains unknown (7). The
most recently recognized species, B. petrii, was described
in 2001 (2) and was isolated from an anaerobic bioreactor
culture enriched from river sediment. This description was
based on a single isolate and, to our knowledge, no further
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isolates of this species have been previously reported from
any source. 
The source of infection of the strain described here and
the pathogenic role of B. petrii are currently unknown.
However, the identification and characterization of further
clinical isolates should help determine the reservoir and
virulence potential of this intriguing species.
Addendum
A clinical isolate of a new species of Bordetella,
Bordetella ansorpii sp. nov, has recently been reported
(14). Phylogenetically, it appears to be more closely relat-
ed to B. petrii than to other members of the genus.
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